Macular Degeneration-AAP 2023: Macular Degeneration: A Progressive Retinal Disorder |
Submission link | https://easychair.org/conferences/?conf=maculardegenerationa0 |
Abstract registration deadline | February 19, 2023 |
Submission deadline | March 20, 2023 |
About the book
Age-related macular degeneration is a common cause of vision loss in older adults, and it is typically classified into two types: wet and dry. Wet AMD is characterized by the growth of new blood vessels and leakage from the abnormal vessels, which can lead to significant vision loss.
Recent advancements in the understanding of the molecular mechanisms underlying wet AMD have led to the development of several promising therapeutic drugs, such as anti-vascular endothelial growth factor (VEGF) agents. These drugs have been shown to effectively block the development of new blood vessels and reduce leakage from abnormal vessels, leading to significant improvement in vision in many patients.In addition to these drugs, other treatments, such as photodynamic therapy and laser therapy, may also be used to treat wet AMD, depending on the individual case. It's important to note that early detection and prompt treatment are critical for the best outcomes in managing wet AMD.
The main goal of this book will provide a comprehensive overview of the current state of research on age-related macular degeneration (AMD) and the latest advances in its diagnosis and treatment. The book will likely cover a wide range of topics, including the various treatment options that are currently available, as well as those that are still in development.
Publication fee
Zero publication/processing fee
Submission Guidelines
All papers must be original and not simultaneously submitted to another journal, book or conference.
Table of content
- AMD Etiology, Pathophysiology and stages
- Risk factors for progression of age-related macular degeneration
- The Role of Inflammation in Age-Related Macular Degeneration.
- Genetics of age-related macular degeneration (AMD)
- Neovascular Age-Related Macular Degeneration (nAMD)
- Human Plasma Metabolomics in Age-Related Macular Degeneration
- Conventional Diagnosis techniques and reports
- Imaging and artificial intelligence for progression of age-related macular degeneration.
- Biomarkers in AMD
- Age-Related Macular Degeneration: Symptoms & Current Treatment/Conventional therapy
- Novel approach for management of age-related macular degeneration
- Current intravitreal therapy for AMD
- Nanotechnology: revolutionizing the delivery of drugs to treat age-related macular degeneration
- Gene therapies for age-related macular degeneration.
- Anti-VEGF Therapy for Age-Related Macular Degeneration
- The Role of Dysregulated miRNAs in the Pathogenesis, Diagnosis and Treatment of Age-Related Macular Degeneration.
- Carotenoids in the Management of Age-Related Macular Degeneration
- Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration
Editor
1. Dr. Bhupendra Prajapati, Shree S.K.Patel College of Pharmaceutical Education and Research, Ganpat University, Gujarat, India
2. Dr. Rishabha Malviya, Galgotias University, Greater Noida, India.
3. Dr. Himanshu Paliwal, Drug Delivery System Excellence Center and Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Thailand.
4. Prof. Sonali Sundram, Galgotias University, Greater Noida, India.
Important Dates
Abstract Submission: 10th March 2023
Abstract Acceptance notification: 15th March 2023
Full chapter Submission: 30th May 2023
Review Notification od chapter: 15th June 2023
Revise Chapter submission: 30th June 2023
Publication
Macular Degeneration: A Progressive Retinal Disorder (Macular Degeneration-AAP 2023) will be published by Apple Academic Press/Taylor and Francis Group
Contact
All questions about submissions should be emailed to: "editor.rishabha@gmail.com" or "bhupen27@gmail.com"/ +91-9450352185 (for WhatsApp only)